News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Acrivon Therapeutics reported a Q2 2026 net loss of $18.0 million, which translates to $(0.43) per share, significantly beating analyst estimates by 14% and narrowing losses by 21.82% year-over-year. The improved financial performance was attributed to reduced R&D and G&A expenses. The company holds …
Acrivon Therapeutics (NASDAQ:ACRV) reported its quarterly earnings, posting a loss of $0.43 per share, which beat analyst expectations by $0.06. Despite this, shares declined by 0.6% to $1.72 during midday trading. The company maintains a "Moderate Buy" consensus rating from analysts, with an average …
* Acrivon Therapeutics press release [https://seekingalpha.com/pr/20617353-acrivon-reports-second-quarter-2026-financial-results-and-highlights-upcoming-2026-clinical] (ACRV [https://seekingalpha.com/symbol/ACRV]): Q2 GAAP EPS of -$0.43 beats by $0.07. * As of June 30, 2026, the company had cash, cash equivalents and investments of $90.0 million, which is expected to fund operating expenses and capital expenditure requirements …
Acrivon Therapeutics announced its second-quarter 2026 financial results, reporting a net loss of $18.0 million and $90.0 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q4 2027. The company highlighted upcoming clinical data catalysts for ACR-368, including a Phase …
This article provides an earnings forecast for Acrivon Therapeutics Inc (ACRV), including analyst ratings, price targets, and expected EPS and revenue figures. Based on ratings from 8 analysts, the stock has a "Buy" trend with a target price of USD 11.50, representing a potential …
Acrivon Therapeutics, Inc. announced the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into the randomized dose expansion portion of its Phase 1/2 study. The decision follows observed clinical activity and a favorable safety profile during dose escalation, including durable responses in heavily pretreated lung cancer …
This article provides current stock information for Acrivon Therapeutics Inc (ACRV), including its market capitalization and recent stock performance. It notes a slight decrease in stock price and indicates that more news, earnings, and analyst ratings will be available soon. The page serves as …
Acrivon Therapeutics, Inc. is projected to report a loss of 50 cents per share in its upcoming earnings. This information is provided as an earnings preview. The article encourages readers to access the full report for more details.
Acrivon Therapeutics, Inc.'s Chief Financial Officer, Adam D. Levy, sold 1,142 shares of common stock at $1.57 per share on August 4, 2026. This sale was automatically conducted to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units. Following this transaction, …
Acrivon Therapeutics Inc. (NASDAQ:ACRV) has advanced its experimental cancer drug ACR-2316 to the randomized dose expansion phase of its Phase 1/2 study, selecting 120 mg and 160 mg oral doses. This decision follows successful dose escalation in 35 subjects, where the WEE1/PKMYT1 inhibitor showed …
Acrivon Therapeutics announced that its drug candidate, ACR-2316, a WEE1/PKMYT1 inhibitor, has advanced to randomized dose expansion in its Phase 1/2 study. This progression is based on a favorable safety profile and observed clinical activity, including tumor shrinkage and partial responses, with three lung …
Acrivon Therapeutics (ACRV) is a clinical-stage biopharmaceutical company focused on oncology medicines using its generative phosphoproteomics platform. The company's stock shows high volatility and is currently unprofitable, with revenue forecast to grow but earnings expected to decline. Key developments include clinical trial progress for …
This article provides a technical analysis of Acrivon Therapeutics Inc (ACRV), covering its stock performance, market capitalization, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on indicators like MACD, RSI, KDJ, and moving averages. The analysis suggests …
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) experienced a significant 47.6% drop in short interest in July, settling at 1.49 million shares, representing 3.9% of outstanding shares. Despite trading at $1.47 with a $62.7 million market cap, the company's Q1 loss of $0.49 per share met analyst …
The article discusses the revenue breakdown of Acrivon Therapeutics Inc (ACRV), including business segments, regional revenue, and profit contribution. However, it states that relevant data for these categories have not yet been disclosed by the company. The page provides general company information such as …
Acrivon Therapeutics Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on precision oncology medicines. The article provides real-time quotes, trading strategies, and related analysis for ACRV, including financial indicators, analyst ratings, and company information. According to 8 analysts, Acrivon Therapeutics has a "Buy" rating …
This TradingKey article provides a detailed cash flow statement for Acrivon Therapeutics Inc (ACRV), including quarterly and annual data for operating, investing, and financing activities. It also defines key cash flow metrics like operating cash flow, investing cash flow, financing cash flow, and free …
The article provides a valuation analysis for Acrivon Therapeutics Inc (ACRV), focusing on its PE, PB, and Fair Value metrics. However, it notes that relevant data for P/E, P/B, and P/CF have not yet been disclosed by the company. The current stock price, market …
This article reports on a Form 4 filing for Acrivon Therapeutics Inc. (ACRV) on July 24th. The filing indicates insider transaction activity for the company. The stock symbol ACRV is noted to have decreased by 4.19%.
Acrivon Therapeutics' Chief Legal Officer, Mary Miller, sold 573 shares of common stock at $1.76 per share on July 21, 2026. This sale was automatically executed to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units. After this transaction, Miller still …
Mary Miller, Chief Legal Officer at Acrivon Therapeutics Inc., sold 573 shares of company stock for $1,008 to cover tax withholdings. Following the sale, Miller still holds 82,194 shares, while the stock has experienced significant volatility and is down approximately 31% year-to-date. In related …
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has received an average analyst rating of "Moderate Buy" from five analysts, with a consensus 12-month price target of $11.67. The company's stock was trading at $1.67, with a market cap of approximately $71.5 million, significantly below its 12-month high. …
Acrivon Therapeutics will present at the AACR D3 Conference, showcasing its AP3 platform for drug discovery and development. The presentations will include mechanistic data on ACR-2316, a WEE1/PKMYT1 inhibitor, highlighting its potent single-agent activity and superior therapeutic index. Early clinical responses for ACR-2316 across …
Acrivon Therapeutics will present Phase 1/2 data for its drug candidate ACR-2316 at the AACR D3 Conference, highlighting its AP3 platform for drug discovery. Early observations for ACR-2316, a WEE1/PKMYT1 inhibitor, show tumor shrinkage, partial responses, and durable clinical benefit in AP3-predicted tumor types, …
Search by ticker symbol or company name and select a result to open its chart.